For the first time in more than a decade, the FDA has approved a new first-line treatment for patients with metastatic
#pancreaticcancer, called NALIRIFOX.
After a clinical trial showed a positive survival benefit, the combination chemotherapy called NALIRIFOX is now approved for patients who have not received any previous treatment. For a disease with limited treatment options, this is exciting news. 💜
We've answered some of the most common questions related to this new treatment option at
pcan.at/s2nut9.
If you have additional questions, you can contact PanCAN Patient Services at 📱 877-2- PANCAN or 📧 patientservices@pancan.org. Our Case Managers can help you understand your options and connect you with resources to learn more.
ALT FDA Approves New First-line Treatment Option for Metastatic Pancreatic Cancer